Flexibility and precision in modern clinical monitoring
In today’s clinical research landscape, efficiency and accuracy in visit monitoring are crucial for ensuring data quality and regulatory compliance.
However, many clinical operations teams, CROs, and pharmaceutical sponsors still face system limitations — rigid forms, inflexible workflows, and reports that fail to reflect the specific needs of each study.
TrialPal MoVi was designed to transform clinical visit monitoring with highly customizable functionalities tailored to the nature, complexity, and unique requirements of every protocol.
Different studies, one standard of quality
Each clinical trial brings its own complexity:
- Varying visit schedules and checkpoints.
- Sites with multidisciplinary teams and different experience levels.
- Regulatory requirements specific to each country or agency (FDA, EMA, INVIMA).
Yet, most platforms rely on generic templates, forcing monitors to adapt rather than the other way around — leading to inefficiencies, errors, and unnecessary rework.
As decentralized clinical trials (DCTs) continue to grow at double-digit rates (ClinicalTrials.gov; TransCelerate BioPharma, 2024), customization is no longer a luxury—it’s an operational necessity.
TrialPal MoVi: Modular and adaptable monitoring management
TrialPal MoVi delivers a flexible, modular approach that enables unique and efficient monitoring experiences.
From study setup to report consolidation, the platform empowers clinical operations teams with advanced configurability and flexibility.
Flexible project and site setup
Each project can be defined with its own organizational structure:
- Sites, investigators, and associated staff.
- Monitors and user roles with differentiated access levels.
- Independent report templates by visit type (initiation, monitoring, close-out).
Fully customizable visit forms
TrialPal MoVi forms include dynamic, configurable fields such as:
- Text, numbers, dates, single/multiple selections, and checkboxes.
- Automatic validation rules for consistency, required fields, and value ranges.
- Custom tables and lists for structured data capture.
This flexibility allows each CRO or sponsor to build forms that reflect their operational language and collect only the information that truly matters for each protocol.
Data inheritance and traceability across visits
TrialPal MoVi enables data to be carried forward between visits, ensuring full traceability and continuity of care. This is essential to:
- Track protocol deviations.
- Monitor open findings and action items.
- Avoid redundant data entry or transcription errors.
Automation and regulatory compliance
With configurable validation rules, TrialPal MoVi reduces human error and ensures compliance with ICH-GCP, FDA, and EMA standards.
Built-in data validation enhances integrity and simplifies audits or inspections.
Customization in action: a real-world example
A CRO managing both oncology and cardiovascular studies can configure unique templates for each:
- Oncology: include dedicated fields for adverse events and dose modifications.
- Cardiovascular: implement automatic validations for blood pressure and ECG ranges.
Both projects operate within TrialPal MoVi, but with independent logic — improving monitor efficiency, data consistency, and overall study quality.
Measurable benefits of personalized monitoring
- Operational efficiency: less time configuring, more time analyzing.
- Regulatory compliance: built-in validation and full traceability.
- Data quality: forms aligned with study-specific needs.
- Scalability: templates can be reused or adapted for new projects.
- User satisfaction: intuitive interface aligned with monitoring workflows.
Personalization as the new standard in clinical trial management
The clinical research industry is shifting toward configurable CTMS and eSource platforms, driven by digital transformation and the expansion of DCTs.
TrialPal MoVi leads this shift by combining technology, flexibility, and control, enabling research teams to monitor smarter, not harder.
Conclusion
Customization in clinical monitoring is no longer optional — it’s the key to achieving efficiency, accuracy, and compliance.
With TrialPal MoVi, CROs and sponsors can adapt the tool to their workflows, rather than adapting their workflows to the tool.
Book a demo today
References
- ICH E6(R3) Good Clinical Practice Draft Guideline, 2024
- FDA: Guidance for Clinical Investigators, Sponsors, and IRBs, 2023
- EMA: Reflection Paper on Decentralized Elements in Clinical Trials, 2022
- TransCelerate BioPharma: Digital Data Flow Initiative, 2024
- ClinicalTrials.gov – Statistics and Trends 2024
